Trials / Available
AvailableNCT07088159
Intermediate-size Patient Population Expanded Access Protocol
Intermediate-size Patient Population Expanded Access Protocol for SPG302 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Spinogenix · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- —
Summary
The purpose of this Expanded Access Program is to provide SPG302 to ALS patients who are not eligible to enroll in an ALS clinical trial. This Expanded Access Program will assess safety and tolerability, and clinical efficacy of SPG302.
Detailed description
This is a multi-site, intermediate-size patient population expanded access protocol developed to provide compassionate use access to SPG302 to adult patients with ALS who have progressed following available standard of care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPG302 | 300 mg SPG302 will taken by mouth once daily. |
Timeline
- First posted
- 2025-07-28
- Last updated
- 2026-03-24
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT07088159. Inclusion in this directory is not an endorsement.